This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Magee, W. C. Articles by Evans, D. H. Search for Related Content PubMed PubMed Citation Articles by Magee, W. C. Articles by Evans, D. H.

Mechanism of Inhibition of Vaccinia Virus DNA Polymerase by Cidofovir Diphosphate

Department of Medical Microbiology and Immunology, Faculty of Medicine and Dentistry, The University of Alberta, Edmonton, Alberta T6G 2H7, Canada,¹ San Diego VA Healthcare System, School of Medicine, University of California, San Diego, La Jolla, California 92093-0676²

Received 10 January 2005/ Returned for modification 12 April 2005/ Accepted 17 May 2005

Cidofovir (CDV) is a broad-spectrum antiviral agent that has been approved for clinical use in the treatment of cytomegalovirus retinitis. It has also been used off label to treat a variety of other viral infections, including those caused by orf and molluscum contagiosum poxviruses. Because it is a dCMP analog, CDV is thought to act by inhibiting viral DNA polymerases. However, the details of the inhibitory mechanism are not well established and nothing is known about the mechanism by which the drug inhibits poxvirus DNA polymerases. To address this concern, we have studied the effect of the active intracellular metabolite of CDV, CDV diphosphate (CDVpp), on reactions catalyzed by vaccinia virus DNA polymerase. Using different primer-template pairs and purified vaccinia virus polymerase, we observed that CDV is incorporated into the growing DNA strand opposite template G's but the enzyme exhibits a lower catalytic efficiency compared with dCTP. CDV-terminated primers are also good substrates for the next deoxynucleoside monophosphate addition step, but these CDV + 1 reaction products are poor substrates for further rounds of synthesis. We also noted that although CDV can be excised from the primer 3' terminus by the 3'-to-5' proofreading exonuclease activity of vaccinia virus polymerase, DNAs bearing CDV as the penultimate 3' residue are completely resistant to exonuclease attack. These results show that vaccinia virus DNA polymerase can use CDVpp as a dCTP analog, albeit one that slows the rate of primer extension. By inhibiting the activity of the proofreading exonuclease, the misincorporation of CDV could also promote error-prone DNA synthesis during poxvirus replication.

This article has been cited by other articles:

• Magee, W. C., Aldern, K. A., Hostetler, K. Y., Evans, D. H. (2008). Cidofovir and (S)-9-[3-Hydroxy-(2-Phosphonomethoxy)Propyl]Adenine Are Highly Effective Inhibitors of Vaccinia Virus DNA Polymerase When Incorporated into the Template Strand. Antimicrob. Agents Chemother. 52: 586-597 [Abstract] [Full Text]  
• Hamilton, M. D., Nuara, A. A., Gammon, D. B., Buller, R. M., Evans, D. H. (2007). Duplex strand joining reactions catalyzed by vaccinia virus DNA polymerase. Nucleic Acids Res 35: 143-151 [Abstract] [Full Text]  
• Kornbluth, R. S., Smee, D. F., Sidwell, R. W., Snarsky, V., Evans, D. H., Hostetler, K. Y. (2006). Mutations in the E9L Polymerase Gene of Cidofovir-Resistant Vaccinia Virus Strain WR Are Associated with the Drug Resistance Phenotype. Antimicrob. Agents Chemother. 50: 4038-4043 [Abstract] [Full Text]  
• Andrei, G., Gammon, D. B., Fiten, P., De Clercq, E., Opdenakker, G., Snoeck, R., Evans, D. H. (2006). Cidofovir Resistance in Vaccinia Virus Is Linked to Diminished Virulence in Mice. J. Virol. 80: 9391-9401 [Abstract] [Full Text]